Gain-of-Function Mutation of Tristetraprolin Impairs Negative Feedback Control of MacrophagesIn Vitroyet Has Overwhelmingly Anti-Inflammatory ConsequencesIn Vivo.
O'Neil JD., Ross EA., Ridley ML., Ding Q., Tang T., Rosner DR., Crowley T., Malhi D., Dean JL., Smallie T., Buckley CD., Clark AR.
The mRNA-destabilizing factor tristetraprolin (TTP) binds in a sequence-specific manner to the 3' untranslated regions of many proinflammatory mRNAs and recruits complexes of nucleases to promote rapid mRNA turnover. Mice lacking TTP develop a severe, spontaneous inflammatory syndrome characterized by the overexpression of tumor necrosis factor and other inflammatory mediators. However, TTP also employs the same mechanism to inhibit the expression of the potent anti-inflammatory cytokine interleukin 10 (IL-10). Perturbation of TTP function may therefore have mixed effects on inflammatory responses, either increasing or decreasing the expression of proinflammatory factors via direct or indirect mechanisms. We recently described a knock-in mouse strain in which the substitution of 2 amino acids of the endogenous TTP protein renders it constitutively active as an mRNA-destabilizing factor. Here we investigate the impact on the IL-10-mediated anti-inflammatory response. It is shown that the gain-of-function mutation of TTP impairs IL-10-mediated negative feedback control of macrophage functionin vitroHowever, thein vivoeffects of TTP mutation are uniformly anti-inflammatory despite the decreased expression of IL-10.